TD Cowen has raised Amgen's price target from $381 to $383, maintaining a "buy" rating. Currently, the stock has a "Moderate Buy" average rating, with a consensus price target of $323.05. Amgen reported a quarterly EPS of $5.58, exceeding estimates, and announced a dividend of $2.25 per share, payable on December 9th.